Citius Pharmaceuticals, Inc.
CTXR
$1.32
$0.064.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.87% | -27.77% | -5.82% | -8.51% | -24.70% |
| Total Depreciation and Amortization | -21.59% | 7.49% | 7.45% | 7.40% | 7.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.49% | -28.59% | -30.57% | -22.41% | 151.55% |
| Change in Net Operating Assets | 166.40% | 251.07% | 1,261.24% | 1,942.71% | 52.94% |
| Cash from Operations | 35.38% | 41.70% | 22.97% | 13.05% | 12.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -23.69% | -- | -- | -92.95% | -0.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -218.81% | -- |
| Cash from Financing | -16.40% | -- | -- | -535,128.57% | -0.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.29% | 86.21% | 64.93% | -115.55% | 26.93% |